

ACHIEVEMENT OF LONG-TERM TREATMENT GOALS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF INDUCTION AND MAINTENANCE PHASE 3 TRIALS

Brian G. Feagan

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

Post hoc analysis of upadacitinib trials in moderately to severely active ulcerative colitis shows that a composite endpoint of endoscopic remission, complete symptom resolution, and quality of life remission was achieved by 18.3% of patients on upadacitinib 30 mg at 52 weeks of maintenance therapy.

KEY POINTS

- At maintenance week 52, 18.3% of induction responders achieved the composite endpoint with upadacitinib 30 mg, 13.1% with upadacitinib 15 mg, and 4.5% with placebo ($p < 0.001$ for both doses vs placebo).
- The composite endpoint combined endoscopic remission (endoscopic score 0), complete symptom resolution (stool frequency ≤ 1 , rectal bleeding 0, no urgency or abdominal pain), and IBDQ remission (total score ≥ 170).
- At induction week 8, 6.4% of patients on upadacitinib 45 mg achieved the composite endpoint compared to 0.9% on placebo ($p < 0.001$).
- Among patients who did not achieve the composite endpoint at the start of maintenance, 16.2% on upadacitinib 30 mg and 12.3% on upadacitinib 15 mg achieved it by week 52, compared to 2.9% on placebo.
- This post hoc analysis of the U-ACHIEVE and U-ACCOMPLISH trials may be relevant to clinicians treating moderately to severely active ulcerative colitis who are interested in long-term treatment outcomes combining endoscopic, symptomatic, and quality of life measures.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/77f37556-743c-11ee-b38c-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.